ATE243252T1 - Pharmazeutische zusammensetzung enthaltend durch pim aktivierten nkt zellen, und ihr verwendung in der therapie - Google Patents

Pharmazeutische zusammensetzung enthaltend durch pim aktivierten nkt zellen, und ihr verwendung in der therapie

Info

Publication number
ATE243252T1
ATE243252T1 AT00920847T AT00920847T ATE243252T1 AT E243252 T1 ATE243252 T1 AT E243252T1 AT 00920847 T AT00920847 T AT 00920847T AT 00920847 T AT00920847 T AT 00920847T AT E243252 T1 ATE243252 T1 AT E243252T1
Authority
AT
Austria
Prior art keywords
pim
pharmaceutical composition
therapy
composition containing
nkt cells
Prior art date
Application number
AT00920847T
Other languages
English (en)
Inventor
Irina Apostolov
Gabriel Gachelin
Philippe Kourilsky
Yousuke Takahama
Original Assignee
Inst Nat Sante Rech Med
Pasteur Institut
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inst Nat Sante Rech Med, Pasteur Institut filed Critical Inst Nat Sante Rech Med
Application granted granted Critical
Publication of ATE243252T1 publication Critical patent/ATE243252T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AT00920847T 1999-04-19 2000-04-19 Pharmazeutische zusammensetzung enthaltend durch pim aktivierten nkt zellen, und ihr verwendung in der therapie ATE243252T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9904897A FR2792205B1 (fr) 1999-04-19 1999-04-19 Composition pharmaceutique comprenant des cellules nkt activees par des pim, et son utilisation en therapie
PCT/FR2000/001029 WO2000063348A2 (fr) 1999-04-19 2000-04-19 Composition pharmaceutique comprenant des cellules nkt activees par des pim, et son utilisation en therapie

Publications (1)

Publication Number Publication Date
ATE243252T1 true ATE243252T1 (de) 2003-07-15

Family

ID=9544579

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00920847T ATE243252T1 (de) 1999-04-19 2000-04-19 Pharmazeutische zusammensetzung enthaltend durch pim aktivierten nkt zellen, und ihr verwendung in der therapie

Country Status (12)

Country Link
US (2) US7052909B1 (de)
EP (2) EP1346725A1 (de)
JP (1) JP2003502284A (de)
AT (1) ATE243252T1 (de)
CA (1) CA2368029A1 (de)
DE (1) DE60003417T2 (de)
DK (1) DK1171578T3 (de)
ES (1) ES2206221T3 (de)
FR (1) FR2792205B1 (de)
HK (1) HK1044795B (de)
PT (1) PT1171578E (de)
WO (1) WO2000063348A2 (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ505538A (en) * 2000-07-03 2004-12-24 Malaghan Inst Of Medical Res A vaccine comprising immunogenic acyl glyceryl phosphatidylinositol manno-oligosaccharide (PIM); and the use of PIM for inducing an immune response in a patient effective in the prevention or treatment of Th2-mediated diseases or disorders such as asthma
FR2815641B1 (fr) * 2000-10-24 2002-12-27 Pasteur Institut Procede de criblage de molecules actives dans la prevention et le traitement des lesions atherosclereuses et ses applications
ES2340270T3 (es) * 2002-08-23 2010-06-01 Gabriele Prof. Dr. Multhoff Granzima b dependiente de peptidos hsp70/hsp70 como inductora de apoptosis en celulas tumorales.
US20050069546A1 (en) * 2003-09-30 2005-03-31 Yaron Ilan Educated NKT cells and their uses in the treatment of immune-related disorders
JP2008503468A (ja) * 2004-06-18 2008-02-07 ジェネンテック・インコーポレーテッド Ａｐｏ２ｌレセプターアゴニストおよびｎｋ細胞活性化因子の使用方法
FR2908658B1 (fr) * 2006-11-20 2011-11-11 Centre Nat Rech Scient Composition pour la prevention et/ou le traitement des maladies associees a la surexpression du tnf et/ou de l'il-12

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6239116B1 (en) * 1994-07-15 2001-05-29 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
DE69840528D1 (de) * 1997-04-10 2009-03-19 Kyowa Hakko Kirin Co Ltd NKT-Zellenaktivatoren, die Alpha-Glycosylceramide enthalten
AU749218C (en) * 1997-09-12 2003-10-30 Brigham And Women's Hospital Synthetic antigens for CD1-restricted immune responses
JP2002511421A (ja) * 1998-04-13 2002-04-16 ザ ブライハム アンド ウイミンズ ホスピタル， インコーポレイテッド Ｃｄ−１抗原およびｔ細胞刺激化合物を含むワクチン組成物およびその使用方法

Also Published As

Publication number Publication date
ES2206221T3 (es) 2004-05-16
HK1044795A1 (en) 2002-11-01
DE60003417T2 (de) 2004-05-06
CA2368029A1 (fr) 2000-10-26
US7052909B1 (en) 2006-05-30
JP2003502284A (ja) 2003-01-21
US20060263376A1 (en) 2006-11-23
EP1171578B1 (de) 2003-06-18
EP1346725A1 (de) 2003-09-24
DE60003417D1 (de) 2003-07-24
HK1044795B (zh) 2003-10-10
WO2000063348A3 (fr) 2000-12-28
PT1171578E (pt) 2003-11-28
EP1171578A2 (de) 2002-01-16
FR2792205B1 (fr) 2001-07-27
WO2000063348A2 (fr) 2000-10-26
FR2792205A1 (fr) 2000-10-20
DK1171578T3 (da) 2003-10-13

Similar Documents

Publication Publication Date Title
CO5570656A2 (es) Liberacin controlada de una sustancia activa a un entorno rico en grasa
DE69433818D1 (de) Kombinierte wirkstoffe als methode zur gezielten wirkstoff-freisetzung
DE60031793D1 (de) Doxorubicin- und daunorubicin-enthaltende, zytotoxische mittel und deren therapeutische anwendung
BRPI0518460A2 (pt) mÉtodo para tratar emergÊncia alÉrgica em um paciente, dispositivo de distribuiÇço de droga contendo uma soluÇço de epinefrina, e, kit para tratar uma emergÊncia alÉrgia'
BRPI0618918B8 (pt) uso de um primeiro composto e um segundo composto para tratar uma condição de glicose sanguínea
KR20150008858A (ko) 생체 광자성 조성물들, 키트들 및 방법들
EP2305276A3 (de) Zellen aus Lipoaspirat und ihre Verwendung zur Therapie
DE60319702D1 (de) Polymeraffinitätsmatrix, verfahren zu ihrer herstellung und verwendung
DE69941996D1 (de) Pharmazeutische zusammenstellung zur verwendung in notbehandlungen und dessen herstellungsverfahren
CN1299279A (zh) 新型用途
DE60003417D1 (de) Pharmazeutische zusammensetzung enthaltend durch pim aktivierten nkt zellen, und ihr verwendung in der therapie
ATE421319T1 (de) Mit s-nitrosothiol angereicherte erythrocyten und deren verwendung
ATE513555T1 (de) Pharmazeutische kombination aus g-csf und plgf für blutstammzellen
US20200405858A1 (en) Modulation of biophotonic regimens
FI972004A0 (fi) Implantoitava laite vaikuttavien aineiden antamiseen kasveille
CO5640120A2 (es) Formulacion y metodods para el tratamiento de trombocitemia
FI962550A0 (fi) Deuterisoidut vaikuttavat aineet transdermaalisessa käyttötarkoituksessa
DE69528473D1 (de) Verwendung von hepatozyten-wachstumsfaktor zur induzierung der proliferation und differenzierung von hämatopoietischen zellen
SHIRAI et al. Difference in Cell Viability between with and without Visible Light-irradiation by Camphorquinone (CQ)-containing Medium
Hong et al. Assessment of superoxide-mediated release of vascular-inhibitory factor (s) from endothelial cells by using a two-bath system
Iwamoto et al. Phenformin stimulation of insulin binding to human cultured lymphocytes
Lara et al. understanding the role of adipocytes and the tumor microenvironment on doxorubicin therapy of breast cancer in a tissue engineered, patient specific, high-throughput biomimetic platform
TR200100020T2 (tr) Gliserol trinitrat içerikli bileşim, imalat yöntemleri ve kullanımı
ATE319410T1 (de) Verfahren zur kosmetischen behandlung von keratinischen materialen, wobei aromatische wirkstoffe aus aromatischen polymerpartikeln kontrolliert freigesetzt werden
TH54857A3 (th) องค์ประกอบตัวใหม่และการใช้

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1171578

Country of ref document: EP

REN Ceased due to non-payment of the annual fee